Key clinical point: No association was observed between runt-related transcription factor 1 gene mutation ( RUNX1+) and inferior outcomes after allogeneic stem cell transplantation (alloSCT) in the first complete remission (CR). These findings suggest that early cell transplantation could probably overcome the negative effects of RUNX1 mutation on patients with acute myeloid leukemia (AML).
Major finding: Patients with vs. without RUNX1 mutation had similar rates of overall survival (OS; P = .65), leukemia-free survival ( P = .60), and relapse ( P = .83) after alloSCT in the first CR.
Study details: Findings are from a retrospective analysis of 674 adult patients with AML (de novo AML, n=584) who underwent alloSCT in the first CR between January 2013 and June 2019.
Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflicts of interest.
Source: Waidhauser J et al. Bone Marrow Transplant. 2021 May 31. doi: 10.1038/s41409-021-01322-w .